CTN New England Consortium Node

Affiliated Faculty: Marek Chawarski, PhD; Edouard Coupet II, MD, MS; E. Jennifer Edelman, MD, MHS; David Fiellin, MD; Kathryn Hawk, MD, MHS; Ryan McNeil, PhD; Edward Melnick, MD, MHS; Patrick O’Connor, MD; Gail D’Onofrio, MD, MS; Jeanette Tetrault, MD

The National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) was created in 1999 to bridge the gap between substance use research and community-based treatment. The NIDA CTN New England Consortium Node, led by Yale Program in Addiction Medicine core faculty member, Gail D’Onofrio, MD, MS, and by Roger D. Weiss, MD, is one of sixteen across the country working with behavioral, pharmacological, and integrated treatment interventions, to study effectiveness and disseminate evidenced-based treatments. The Node consists of a collaboration of esteemed institutions and community treatment providers committed to excellence in patient-centered interventions and dissemination. The institutions bring a multidisciplinary team comprising psychiatry, psychology, emergency medicine, medicine, and pediatrics.

• Opioid Use Disorder in the Emergency Department
• Emergency Department Connection to Care with Buprenorphine for Opioid Use Disorder (ED-CONNECT)
• CTN0131: Office-Based Methadone versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder – a Pragmatic Hybrid Effectiveness/Implementation Trial
• CTN0116: Pharmacist-Integrated Model of Medication Treatment for Opioid Use Disorder
• CTN099: Emergency Department-Initiated buprenorphine and VAlidaTIOn Network Trial (ED-INNOVATION)